Last reviewed · How we verify

Lateral canthal lines — Treatment Landscape & Competitive Intelligence

Lateral canthal lines (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Lateral canthal lines, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Xeomin INCOBOTULINUMTOXINA Merz Pharms Acetylcholine Release Inhibitor [EPC] 2015-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Merz Pharms · 1 drug in Lateral canthal lines

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Lateral canthal lines:

Cite this brief

Drug Landscape (2026). Lateral canthal lines — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/lateral-canthal-lines. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing